Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
Bioventus (Nasdaq: BVS) has secured a new $400 million Senior Secured Credit Agreement, comprising a $300 million term loan and a $100 million revolving credit facility, maturing on July 31, 2030. The agreement represents significant improvements over their 2019 Credit Agreement, featuring a 75 basis point reduction in interest margin, generating over $2 million in annual interest savings.
Key enhancements include an increase in revolving credit facility from $40 million to $100 million, and a reduction in annual term loan amortization from 10% to 5%. The company used the proceeds to repay its outstanding $333 million loan balance under the 2019 agreement, utilizing the new term loan, $30 million from the revolving facility, and $3 million cash on hand.
Bioventus (Nasdaq: BVS) ha ottenuto un nuovo Accordo di Credito Senior Garantito da 400 milioni di dollari, composto da un prestito a termine da 300 milioni di dollari e da una linea di credito revolving da 100 milioni di dollari, con scadenza il 31 luglio 2030. Questo accordo rappresenta miglioramenti significativi rispetto all'Accordo di Credito del 2019, con una riduzione del margine di interesse di 75 punti base, generando oltre 2 milioni di dollari di risparmi annuali sugli interessi.
Le principali migliorie includono un aumento della linea di credito revolving da 40 milioni a 100 milioni di dollari e una riduzione dell'ammortamento annuale del prestito a termine dal 10% al 5%. L'azienda ha utilizzato i proventi per rimborsare il saldo residuo del prestito di 333 milioni di dollari previsto dal contratto del 2019, impiegando il nuovo prestito a termine, 30 milioni di dollari dalla linea revolving e 3 milioni di dollari in liquidità disponibile.
Bioventus (Nasdaq: BVS) ha asegurado un nuevo Acuerdo de Crédito Senior Garantizado por 400 millones de dólares, que incluye un préstamo a plazo de 300 millones de dólares y una línea de crédito revolvente de 100 millones de dólares, con vencimiento el 31 de julio de 2030. El acuerdo representa mejoras significativas respecto al Acuerdo de Crédito de 2019, con una reducción de 75 puntos básicos en el margen de interés, generando más de 2 millones de dólares en ahorros anuales por intereses.
Las mejoras clave incluyen un aumento de la línea de crédito revolvente de 40 millones a 100 millones de dólares y una reducción en la amortización anual del préstamo a plazo del 10% al 5%. La compañía utilizó los fondos para pagar el saldo pendiente del préstamo de 333 millones de dólares bajo el acuerdo de 2019, utilizando el nuevo préstamo a plazo, 30 millones de dólares de la línea revolvente y 3 millones de dólares en efectivo disponible.
Bioventus (나스닥: BVS)는 4억 달러 규모의 선순위 담보 신용 계약을 체결했으며, 이는 3억 달러의 기한부 대출과 1억 달러의 회전 신용 한도로 구성되어 있으며, 만기는 2030년 7월 31일입니다. 이 계약은 2019년 신용 계약에 비해 상당한 개선을 이루었으며, 이자 마진이 75 베이시스 포인트 감소하여 연간 200만 달러 이상의 이자 절감 효과를 가져왔습니다.
주요 개선 사항으로는 회전 신용 한도가 4천만 달러에서 1억 달러로 증가했고, 연간 기한부 대출 상환 비율이 10%에서 5%로 감소한 점이 있습니다. 회사는 신규 기한부 대출, 회전 신용 한도에서 3천만 달러, 그리고 보유 현금 300만 달러를 활용하여 2019년 계약에 따른 미상환 대출 잔액 3억 3,300만 달러를 상환했습니다.
Bioventus (Nasdaq : BVS) a obtenu un nouveau contrat de crédit senior garanti de 400 millions de dollars, comprenant un prêt à terme de 300 millions de dollars et une ligne de crédit renouvelable de 100 millions de dollars, arrivant à échéance le 31 juillet 2030. Cet accord représente une amélioration significative par rapport à leur contrat de crédit de 2019, avec une réduction de 75 points de base sur la marge d’intérêt, générant plus de 2 millions de dollars d’économies annuelles d’intérêts.
Les améliorations clés incluent une augmentation de la ligne de crédit renouvelable de 40 millions à 100 millions de dollars, ainsi qu’une réduction de l’amortissement annuel du prêt à terme de 10 % à 5 %. L’entreprise a utilisé les fonds pour rembourser son solde de prêt impayé de 333 millions de dollars dans le cadre de l’accord de 2019, en utilisant le nouveau prêt à terme, 30 millions de dollars de la ligne renouvelable et 3 millions de dollars de liquidités disponibles.
Bioventus (Nasdaq: BVS) hat eine neue Senior Secured Kreditvereinbarung in Höhe von 400 Millionen US-Dollar abgeschlossen, bestehend aus einem 300 Millionen US-Dollar Terminkredit und einer 100 Millionen US-Dollar revolvierenden Kreditfazilität, mit Fälligkeit am 31. Juli 2030. Die Vereinbarung stellt eine deutliche Verbesserung gegenüber der Kreditvereinbarung von 2019 dar, mit einer Reduzierung der Zinsmarge um 75 Basispunkte, was zu über 2 Millionen US-Dollar jährlichen Zinseinsparungen führt.
Wesentliche Verbesserungen umfassen eine Erhöhung der revolvierenden Kreditfazilität von 40 Millionen auf 100 Millionen US-Dollar sowie eine Reduzierung der jährlichen Tilgung des Terminkredits von 10 % auf 5 %. Das Unternehmen nutzte die Erlöse, um den ausstehenden Kreditbetrag von 333 Millionen US-Dollar aus der Vereinbarung von 2019 zurückzuzahlen, wobei der neue Terminkredit, 30 Millionen US-Dollar aus der revolvierenden Kreditfazilität und 3 Millionen US-Dollar an verfügbaren Barmitteln verwendet wurden.
- Interest margin reduced by 75 basis points, saving over $2 million annually
- Revolving credit facility increased from $40M to $100M, providing greater liquidity
- Term loan amortization reduced from 10% to 5% annually
- Extended maturity date to July 31, 2030, providing long-term stability
- Maintains significant debt level with $333M outstanding balance refinanced
Insights
Bioventus' new $400M credit deal lowers interest costs, enhances liquidity, and significantly improves financial flexibility.
Bioventus has successfully executed a comprehensive debt refinancing that delivers multiple financial advantages. The new
This refinancing demonstrates significant improvement in Bioventus' financial position. The company secured better terms that will directly boost cash flow through interest savings while simultaneously providing greater financial flexibility. The
The reduced annual amortization schedule is equally important - cutting principal repayment requirements in half from
The five-year maturity extends the company's debt horizon to 2030, eliminating near-term refinancing risk and providing stability to their capital structure. The improved terms reflect creditors' increased confidence in Bioventus' financial health following what management describes as "significant progress over the past two years to increase profitability, reduce debt, and enhance cash flow."
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into a
Among the many enhancements, the new Credit Agreement provides for additional liquidity through an increase in the revolving credit facility from
“The new Credit Agreement lowers the interest rate on our debt and increases our liquidity, reflecting the significant progress over the past two years to increase our profitability, reduce debt, and enhance cash flow,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “This is expected to further increase our financial flexibility and enable greater optionality for capital deployment moving forward.”
The proceeds resulting from the Credit Agreement were used to repay the outstanding loan balance of
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and X. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal security laws. Any statements contained herein that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning future interest payments, increased liquidity and financial flexibility, options for capital deployment and our business strategy. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events, future trends, and future dates, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated herein include, but are not limited to: we may be unable to successfully commercialize newly developed or acquired products or therapies within expected timeframes; the failure to obtain and maintain required regulatory clearances and approvals could prevent us from commercializing certain of our products; demand for our existing portfolio of products and any new products, line extensions or expanded indications depends on the continued and future acceptance of our products by physicians, patients, third-party payers and others in the medical community; market opportunities and our focus on a limited number of products; failure to achieve and maintain adequate levels of coverage and/or reimbursement for our products or future products, the procedures using our products; pricing and other competitive factors; governments outside the United States might not provide coverage or reimbursement of our products; risks related to product liability claims; fluctuations in demand for our products; issues relating to the supply of our products or their components due to product quality and regulatory compliance issues, including increased costs, disruptions of supply, shortages, contamination or mislabeling; we may face issues with respect to the supply of our products or their components due to product quality and regulatory compliance issues, including increased costs, disruptions of supply, shortages, contamination or mislabeling; our reliance on a limited number of third-party manufacturers to manufacture certain of our products; economic, political, regulatory and other risks related to international sales, manufacturing and operations; unstable political or economic conditions; risks related to our debt; legislative or regulatory reforms; and other the other risks identified in our Annual Report on Form 10-K for the year ended December 31, 2024 as such factors may be updated from time to time in Bioventus’ other filings with the SEC which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Bioventus’ website at https://ir.bioventus.com. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ materially from those set forth in the forward-looking statements.
Investor and Media Inquiries:
Dave Crawford
919-474-6787
Dave.Crawford@bioventus.com
FAQ
What are the key terms of Bioventus's (BVS) new credit agreement in 2025?
How much will Bioventus (BVS) save annually from the new credit agreement?
How did Bioventus (BVS) use the proceeds from the new credit facility?
What is the maturity date of Bioventus's (BVS) new credit agreement?
How much did Bioventus's (BVS) revolving credit facility increase?
